A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients
- PMID: 18378317
- DOI: 10.1016/j.ophtha.2008.02.005
A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients
Abstract
Purpose: Three major glaucoma trials, all using the same Humphrey visual field tests, specified different criteria to define visual field progression. This article compares the performance of these criteria with a reference standard of unanimous classifications by 3 independent glaucoma experts.
Design: Longitudinal, comparative study of diagnostic criteria.
Participants and controls: Two hundred forty-five patients with manifest glaucoma in the Early Manifest Glaucoma Trial (EMGT).
Methods: Visual field series of 1 eye of each of 245 EMGT patients were classified by 3 independent glaucoma specialists as definitely progressing, definitely nonprogressing, or neither. Field series that were classified in the first 2 categories by all 3 experts met the reference standards for the progressing and nonprogressing groups and were analyzed according to the progression criteria of the Advanced Glaucoma Intervention Study (AGIS), the Collaborative Initial Glaucoma Treatment Study (CIGTS), and the EMGT. Sensitivity, specificity, time to progression, and sustainability were calculated.
Main outcome measures: Progression, nonprogression, sensitivity, specificity, time to progression, and sustainability.
Results: Seventy-seven field series were definitely progressing, and 95 series were definitely nonprogressing. Among progressing eyes, 45 (58%) of 77 were identified using AGIS criteria, 58 (75%) of 77 were identified with CIGTS criteria, and 74 (96%) of 77 were identified with EMGT criteria; all comparisons of sensitivities were significant, simultaneous (P<0.001), and pairwise (P<0.01). The specificity for EMGT criteria was 89%, lower (P<0.05) than that of AGIS (98%) and CIGTS (99%) criteria. Median time to progression was considerably shorter with EMGT criteria (33 months; 95% confidence interval [CI], 30-36 months) than with AGIS (66 months; 95% CI, 57-78 months) and CIGTS (55 months; 95% CI, 48-66 months) criteria. Sustainability increased with time after progression; it averaged 79%, 84%, and 81%, respectively, for AGIS, CIGTS, and EMGT criteria during the first year after the first progression and 95%, 100%, and 93% during the fourth year after progression.
Conclusions: The EMGT criteria identified progression earlier and more often than AGIS and CIGTS criteria. Specificity was good for all criteria but was better with AGIS and CIGTS than with EMGT criteria. Sustainability was high for all 3 sets of criteria and best for CIGTS criteria and increased with time after progression.
Similar articles
-
Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment.Ophthalmology. 1999 Feb;106(2):391-5. doi: 10.1016/S0161-6420(99)90052-0. Ophthalmology. 1999. PMID: 9951496
-
Natural history of open-angle glaucoma.Ophthalmology. 2009 Dec;116(12):2271-6. doi: 10.1016/j.ophtha.2009.06.042. Epub 2009 Oct 24. Ophthalmology. 2009. PMID: 19854514 Clinical Trial.
-
Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.Ophthalmology. 2007 Feb;114(2):205-9. doi: 10.1016/j.ophtha.2006.07.060. Epub 2006 Nov 13. Ophthalmology. 2007. PMID: 17097736 Clinical Trial.
-
[Update on prospective glaucoma intervention studies].Klin Monbl Augenheilkd. 2005 Oct;222(10):807-13. doi: 10.1055/s-2005-858210. Klin Monbl Augenheilkd. 2005. PMID: 16240274 Review. German.
-
[Ocular hypertension and glaucoma: the contribution of large studies to daily practice].J Fr Ophtalmol. 2002 Jun;25(6):641-54. J Fr Ophtalmol. 2002. PMID: 12223955 Review. French.
Cited by
-
Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions.Jpn J Ophthalmol. 2023 Nov;67(6):658-667. doi: 10.1007/s10384-023-01020-8. Epub 2023 Aug 19. Jpn J Ophthalmol. 2023. PMID: 37596443
-
Risk factors for progressive visual field loss in primary angle-closure glaucoma: a retrospective cohort study.PLoS One. 2013 Jul 8;8(7):e69772. doi: 10.1371/journal.pone.0069772. Print 2013. PLoS One. 2013. PMID: 23861982 Free PMC article.
-
Low nocturnal diastolic ocular perfusion pressure as a risk factor for NTG progression: a 5-year prospective study.Eye (Lond). 2018 Jul;32(7):1183-1189. doi: 10.1038/s41433-018-0057-8. Epub 2018 Mar 1. Eye (Lond). 2018. PMID: 29491486 Free PMC article.
-
Evidence-based Criteria for Assessment of Visual Field Reliability.Ophthalmology. 2017 Nov;124(11):1612-1620. doi: 10.1016/j.ophtha.2017.04.035. Epub 2017 Jul 1. Ophthalmology. 2017. PMID: 28676280 Free PMC article.
-
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.Prog Retin Eye Res. 2017 Jan;56:107-147. doi: 10.1016/j.preteyeres.2016.10.001. Epub 2016 Oct 20. Prog Retin Eye Res. 2017. PMID: 27773767 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous